Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

Combination of T-Cell Bispecific Antibodies With PD-L1 Checkpoint Inhibition Elicits Superior Anti-Tumor Activity

T-cell Bispecific Antibodies (TCBs) elicit anti-tumor responses by cross-linking T-cells to tumor cells and mediate polyclonal T-cell expansion that is independent of T-cell receptor specificity. TCBs thus offer great promise for patients who lack antigen-specific T-cells or have non-inflamed tumors...

Full description

Bibliographic Details
Main Authors: Johannes Sam, Sara Colombetti, Tanja Fauti, Andreas Roller, Marlene Biehl, Linda Fahrni, Valeria Nicolini, Mario Perro, Tapan Nayak, Esther Bommer, Anne Schoenle, Maria Karagianni, Marine Le Clech, Nathalie Steinhoff, Christian Klein, Pablo Umaña, Marina Bacac
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Oncology
Subjects:
solid tumors
immunotherapy
T-cell bispecific antibody
carcinoembryonic antigen T-cell bispecific antibody
programmed death–ligand 1
combination
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2020.575737/full

Similar Items

Similar Items